Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Shares Outstanding (Entity) data on file, last reported at $143.2 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 3.74% year-over-year to $143.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $143.2 million (up 3.74% YoY) and the FY2025 annual result came in at $138.4 million, up 11.25% from the prior year.
• Shares Outstanding (Entity) advanced to $143.2 million in Q1 2026, from $140.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $143.2 million in Q1 2026 to a low of $105.7 million in Q1 2022.
• A 5-year average of $120.5 million and a median of $124.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) grew 1.1% — and 2024, when it gained 16.81%.
• Tracing ARWR's Shares Outstanding (Entity) over 5 years: stood at $106.1 million in 2022, then climbed by 1.28% to $107.5 million in 2023, then grew by 16.81% to $125.6 million in 2024, then rose by 11.53% to $140.1 million in 2025, then rose by 2.27% to $143.2 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $143.2 million (Q1 2026), $140.1 million (Q4 2025), and $138.4 million (Q3 2025), per Business Quant data.